By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cascadian Therapeutics (Formally known as Oncothyreon) 

2601 Fourth Avenue
Suite 500
Seattle  Washington  98121   U.S.A.
Phone: 206-801-2100 Fax: 206-801-2101



Company News
Cascadian Therapeutics (ONTY)’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation From FDA For Treatment Of Breast Cancer Patients With Brain Metastases 6/8/2017 8:11:38 AM
Cascadian Therapeutics (ONTY) Reports First Quarter 2017 Financial Results Conference Call Scheduled For Today At 8:30 A.M. ET 5/9/2017 8:08:08 AM
Cascadian Therapeutics (ONTY) To Report First Quarter 2017 Financial Results On May 9, 2017 5/1/2017 8:35:35 AM
Cascadian Therapeutics (ONTY) Highlights Preclinical Program Presentations at the AACR Annual Meeting 2017 4/5/2017 11:08:22 AM
Cascadian Therapeutics (ONTY) Announces Changes To Board Of Directors 3/14/2017 8:11:13 AM
Cascadian Therapeutics (ONTY) Announces 2017 Outlook And Recent Drug Portfolio Progress 1/5/2017 7:32:41 AM
Cascadian Therapeutics (ONTY) Amends HER2CLIMB Phase 2 Trial Of Tucatinib In Metastatic HER2-Positive Breast Cancer To Support Registration 12/8/2016 9:38:01 AM
With a New Name and Leader, Cascadian Therapeutics (ONTY) Rejigs Breast Cancer Study to Meet FDA's Standards 12/7/2016 5:55:50 AM
Cascadian Therapeutics (ONTY) Strengthens Management Team With Key Hires, Monique M. Greer And Marc C. Chamberlain, M.D. 11/28/2016 7:10:07 AM
Cascadian Therapeutics (ONTY) Announces Stockholders And Board Of Directors Approve Reverse Stock Split 11/28/2016 7:08:25 AM